Page 7 - Pharma Industry

Trump's 27% tariff on Indian exports: Who gains and who takes the hit?

The US Trump administration has levied a flat 27% tariff on Indian goods with some exemptions. Here how domestic players have been impacted

Lupin announces acquisition of UK-Based Renascience Pharma for GBP 12.3 mn

Renascience, incorporated in 2015, supplies niche branded bio-generic products catering to primary and secondary care in the UK

India may soon train select countries on best drug regulatory practices

The project will be an extension of the CDSCO and NIHFW's ongoing training programmes with drug inspectors from the central and state drug authorities

Bharat Biotech launches India's only integrated cell, gene therapy facility

BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies and inherited blood disorders

Key diabetes drug price crashes by up to 90% as generics enter market

Mankind, Alkem, Glenmark launch generic versions of empagliflozin

Emcure Pharmaceuticals share gains on foraying into daily supplements space

The uptick in the Emcure Pharmaceuticals share price came after the company announced its entry into the daily supplements space with the expansion of its Arth range

Eliminate import duty on drugs from US: Pharma exporters to Centre

The exporters' worry is understandable as the US is the largest export market for Indian pharma accounting for 31.35 percent of India's overall pharma exports worth $27.8 bn

Senores Pharma to acquire 14 ANDAs from Dr Reddy's for US markets

Gujarat-based Senores Pharmaceuticals on Tuesday said it will acquire a basket of 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories for an undisclosed amount. Senores Pharmaceuticals, Inc, USA, a subsidiary of the drug firm, has inked agreements with Dr Reddy's for acquiring the Abbreviated New Drug Applications (ANDAs), the company said in a statement. The basket includes 13 ANDAs approved by the USFDA (US Food and Drug Administration), with one application pending approval, it added. The addressable opportunity of the acquired ANDAs in the US is around USD 421 million as per IQVIA. Senores said the acquisition will be funded through the initial public offer proceeds. This is in line with the objects of the IPO stated in the Red Herring Prospectus, it added. Senores Pharmaceuticals MD Swapnil Shah said the acquired molecules span multiple therapeutic areas with growing consumption. The portfolio consists of controlled substances and the general category of produ

Indian pharma sector's regulatory violation instances fell 11% in '24

In 2014, the share of OAI status globally stood at 6 per cent which has now more than doubled standing at 14 per cent

Indian drugmakers to stay competitive despite US tariff plans: Dr Reddy's

The industry is still waiting for more clarity on any tariffs before taking any action, Prasad said on the sidelines of the BioAsia conference in the Southern Indian state of Telangana

Pharma sector can deliver 100 new drugs by 2047: Zydus chairman

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday. Speaking at an event here, he stressed the need for innovation, capability building, and a focus on societal benefit. "I believe India can deliver 100 new chemical entities or new drugs to the world by 2047 and off course, it will require effort," Patel said while speaking at the SOUL leadership conclave 2025. He termed it a myth that drug discovery requires a billion dollars while emphasising that it is possible with the right approach. Patel also asserted that the people working in an organisation are the most valuable resource and pitched for an environment where people love to work. He also emphasised the evolving nature of leadership, highlighting the importance of humility, vision, and a global perspective. Patel also shared experiences, including the Prime Minister's proactiv

Sun Pharmaceutical seeks shareholder nod for RPTs worth $1 billion

A key component of the transactions includes a $650 million funding arrangement for its U.S. subsidiary, Sun Pharmaceutical Industries Inc. (SPI Inc.), to support business expansion

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Global pharma eyes India's obesity mkt, but weight-loss drugs face hurdles

These drugs belong to a class known as glucagon-like peptide receptor agonists (GLP-1RAs), which mimic a natural hormone that helps regulate blood sugar and appetite

Manufacturers asked to revise MRP for drugs with nil, reduced customs duty

In her budget speech, Finance Minister Nirmala Sitharaman announced the exemption of 36 drugs used to treat cancer, rare diseases, and other severe chronic diseases from the basic customs duty

Analysts bullish on Lupin after Q3; share pops 6%; Goldman Sachs ups target

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising product pipeline

Over 8.5K MSME pharma units get 1-yr breather to adopt Schedule M standards

Mohfw notifies extension till December 31 for companies under Rs 250 cr turnover

Amazon Pharmacy expands medicine access from Andaman to Arunachal Pradesh

Using Amazon's nationwide logistics network, customers can now access a wide range of medicines, with same-day delivery available in 23 cities, including top metros and Tier-II cities

Pharma industry's success relies on innovation, else it will extinct: Goyal

Commerce and Industry Minister Piyush Goyal on Saturday emphasised on the crucial role of innovation in driving the growth of the Indian pharmaceutical industry and warned that without innovation, the industry will be "finished". He also expressed concern that the industry often relies on government incentives to conduct research and development in the sector. "Sadly, our country's mindset has become so weak that for everything we are looking up to the government... we think that only after getting a tax incentive then only we will do research. This is the industry where innovation determines success, whoever will not innovate will be finished," he said, while addressing members of the drug making firms in Mumbai. He also cautioned that if the industry will not innovate, its future is worrisome. The industry will have to keep pace with the changing lifestyle patterns besides demands and needs of the society and patents, Goyal said. He called upon the industry to come forward with

Gland Pharma Q3 result: Net profit rises 7% to Rs 205 cr as expenses drop

Rivals Sun Pharma and Cipla beat third-quarter profit estimates, while Dr Reddy's missed expectations. All three drugmakers saw muted growth in the North American market, including the US